Open, Non Controlled, Multicenter, Firs-in-human Study for the Evaluation of the Safety, Pharmacokinetics and Preliminary Antitumor Activity of GM102 in Patients With Advanced Pretreated Gynecological Cancer
Phase of Trial: Phase I
Latest Information Update: 25 Jul 2017
At a glance
- Drugs GM 102 (Primary)
- Indications Gynaecological cancer
- Focus Adverse reactions; First in man
- Sponsors GamaMabs Pharma
- 18 Jul 2017 Planned number of patients changed from 51 to 84.
- 18 Jul 2017 Planned End Date changed from 1 Dec 2019 to 30 Mar 2020.
- 18 Jul 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Mar 2020.